AccuPulse focuses on cardiac electrophysiology and structural heart interventional devices, offering an integrated product matrix that includes a pulsed field ablation (PFA) system, an AI-driven 3D mapping system, and a range of consumables such as high-density mapping catheters and transseptal tools. Its AccuPulse PFA system consists of a disposable PFA catheter (AccuPulse®) and a multi-channel generator (AccuBlator®), and achieved immediate intraoperative pulmonary vein isolation of 100% with a 12-month success rate of 87.7% in reported follow-up data. The PFA system received NMPA special approval in May 2025, marking the company’s transition from R&D to commercialization; the firm is concurrently advancing registration studies for its 3D mapping platform. The 3D system integrates magnetic-electric localization with intracardiac ultrasound and uses neural-network–based 3D model registration, positioning it as one of the few AI-driven ultrasound-magnetic-electric mapping solutions globally. AccuPulse has pursued clinical outreach across 16 provinces, secured Beijing procurement wins, and established strategic collaborations with partners including Shanghai Pharmaceuticals and Taimei Medical. The company operates R&D centers in China and the U.S., and its leadership team comprises industry veterans from major global medtech firms.

Total raised

$59M

Funding rounds

4

Latest round

Equity

Latest activity

Mar 2026